Fiche publication
Date publication
novembre 2025
Journal
Nanoscale
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GOETZ Jacky
,
Dr LEFEBVRE Olivier
,
Dr HARLEPP Sébastien
,
Dr MERTZ Damien
,
Dr HYENNE Vincent
Tous les auteurs :
Asokan N, Mittelheisser V, Jablonski A, Adam A, Bizeau J, Harlepp S, Hyenne V, Lefebvre O, Goetz JG, Tasso M, Mertz D
Lien Pubmed
Résumé
Mesoporous silica-based nanoparticles (NPs) are promising tools for developing targeted therapeutic interventions in cancer. Endowed with a large pore silica shell suitable for drug encapsulation and with a responsive magnetic core, iron oxide stellate mesoporous silica (IO STMS) NPs stand out. However, their impact and potential toxicity on relevant models have not been carefully tested yet. Herein, we assessed the impact of these IO STMS nanocomposites in a syngeneic metastasis assay in zebrafish. NPs were surface-modified with human serum albumin (HSA) and loaded with or without chemotherapeutic doxorubicin (DOX). , DOX-loaded NPs were expectedly more toxic to zebrafish melanoma (Zmel) cells than NPs without DOX. In zebrafish embryos, the NPs were rapidly distributed through blood circulation and were found to colocalize over time with the vascular endothelium and local macrophages. Surprisingly, the NPs efficiently reduced the outgrowth of Zmel tumoral masses in an experimental metastasis assay in zebrafish embryos regardless of their loading with DOX. The anti-metastatic effect of these NPs was further improved by increasing the amount of HSA coating, resulting in higher embryo survival. Altogether, IO STMS NPs showed promising anti-cancer effects on a relevant zebrafish metastasis model, inhibiting metastatic outgrowth independently of the drug loading. This opens the door to further testing for better exploiting their targeting and drug delivery potentials.
Référence
Nanoscale. 2025 11 27;:
